Literature DB >> 17618704

Oral lipid-based formulations.

David J Hauss1.   

Abstract

Poor drug solubility remains a significant and frequently encountered problem for pharmaceutical scientists. The ability of lipid-based formulations to facilitate gastrointestinal absorption of many poorly soluble drug candidates has been thoroughly documented in the published literature. However, a considerable gap exists between our knowledge of this technology and the know-how required for its application. This commentary provides a comprehensive summary of the development, characterization, and utilization of oral lipid-based formulations, from both physicochemical and biopharmaceutical perspectives. The characteristics of currently available lipid excipients are reviewed in context of their application to the basic lipid-based formulation modalities. The fundamental concepts of in vitro and in vivo evaluation of lipid-based formulations are summarized followed by a forward-looking summary of unrealized opportunities and potential limitations to more widespread use of this technology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618704     DOI: 10.1016/j.addr.2007.05.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  76 in total

Review 1.  Microfabrication technologies for oral drug delivery.

Authors:  Shilpa Sant; Sarah L Tao; Omar Z Fisher; Qiaobing Xu; Nicholas A Peppas; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2011-12-04       Impact factor: 15.470

2.  Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design.

Authors:  Ketan Patel; Sameer Padhye; Mangal Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2011-12-14       Impact factor: 3.246

Review 3.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

4.  Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties.

Authors:  Yulong Lin; Huan Yang; Caiqin Yang; Jing Wang
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

5.  Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica.

Authors:  Ying Wang; Qinfu Zhao; Yanchen Hu; Lizhang Sun; Ling Bai; Tongying Jiang; Siling Wang
Journal:  Int J Nanomedicine       Date:  2013-10-22

6.  Synthesis of a Disulfonated Derivative of Cucurbit[7]uril and Investigations of its Ability to Solubilize Insoluble Drugs.

Authors:  Elizabeth L Robinson; Peter Y Zavalij; Lyle Isaacs
Journal:  Supramol Chem       Date:  2015-05-01       Impact factor: 1.688

7.  Self-nanoemulsifying drug delivery system of nifedipine: impact of hydrophilic-lipophilic balance and molecular structure of mixed surfactants.

Authors:  Yotsanan Weerapol; Sontaya Limmatvapirat; Jurairat Nunthanid; Pornsak Sriamornsak
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

8.  pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System.

Authors:  Sundar Mahajan; Dilpreet Singh; Rashi Sharma; Gurdeep Singh; Neena Bedi
Journal:  AAPS PharmSciTech       Date:  2021-01-05       Impact factor: 3.246

9.  Development of solid self-emulsifying drug delivery system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for lipids.

Authors:  Ankita V Shah; Abu T M Serajuddin
Journal:  Pharm Res       Date:  2012-02-28       Impact factor: 4.200

10.  Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS).

Authors:  Saeed Alqahtani; Alaadin Alayoubi; Sami Nazzal; Paul W Sylvester; Amal Kaddoumi
Journal:  Lipids       Date:  2014-06-17       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.